Anders Hinsby
Geschäftsführer bei Muna Therapeutics ApS
Ursprung des Netzwerks ersten Grades von Anders Hinsby
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 15 | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022.
10
| Holding Company | Biotechnology | 10 |
Muna Therapeutics ApS
 Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020.
10
| Holding Company | Medical/Nursing Services | 10 |
Intomics A/S
 Intomics A/S Miscellaneous Commercial ServicesCommercial Services Intomics A/S provides data analysis solutions to data intensive research projectsa. Its services include advisory service, data analysis, and knowledge management. The firm helps clients in the pharmaceutical industry discover novel and drug targets, identify innovative and discriminative biomarkers, and enhance understanding of the underlying disease-biology at molecular level. The company was founded by Soren Brunak, Kasper Lage, Rasmus Wernersson and Thomas Skot Jensen in 2008 and is headquartered in Kongens Lyngby, Denmark.
7
| Subsidiary | Miscellaneous Commercial Services | 7 |
BI Technology A/S
 BI Technology A/S Investment ManagersFinance BI Technology A/S (BI-T) is a venture capital firm founded in 1969. The firm is headquartered in Copenhagen, Denmark.
5
| Extinct | Investment Managers | 5 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Anders Hinsby
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Chairman Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| University of Copenhagen | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Graduate Degree Corporate Officer/Principal Doctorate Degree | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Founder Private Equity Analyst Private Equity Investor | |
QurAlis Corp.
 QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Chairman Director/Board Member Chief Executive Officer | |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor Consultant / Advisor | |
| Copenhagen Business School | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
Zymenex A/S
 Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Biotechnology | Chairman Director/Board Member Chairman | |
Volastra Therapeutics, Inc.
 Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ABLYNX | Biotechnology | Chairman Director/Board Member | |
| Vrije Universiteit Amsterdam | College/University | Graduate Degree Doctorate Degree | |
STipe Therapeutics ApS
 STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PFIZER, INC. | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal | |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ELOXX PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Founder | |
| SQZ BIOTECHNOLOGIES COMPANY | Biotechnology | Chairman Director/Board Member | |
Azanta A/S
 Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Polaris Growth Management LLC
 Polaris Growth Management LLC Investment ManagersFinance Polaris Partners is an Independent Venture Capital firm founded in 1996 by Stephen D. Arnold, Jonathan A. Flint and Terrance G. McGuire. Polaris Partners is headquartered in Waltham. | Investment Managers | Private Equity Investor Private Equity Investor | |
Eloxx Pharmaceuticals Ltd.
 Eloxx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Flamingo Therapeutics BV
 Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Sales & Marketing Sales & Marketing | |
Warren Pharmaceuticals, Inc.
 Warren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Warren Pharmaceuticals, Inc. develops tissue-protective technologies. The company was founded by Anthony Cerami and Michael Brines on May 17, 2001 and is headquartered in Tarrytown, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NodThera Ltd.
 NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Director/Board Member Chairman | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Chief Tech/Sci/R&D Officer Chief Investment Officer | |
| DISC MEDICINE, INC. | Biotechnology | Director/Board Member Chairman | |
| IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Dynacure SA
 Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Chairman Director/Board Member | |
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Chairman Director/Board Member | |
| INNATE PHARMA | Pharmaceuticals: Major | Corporate Officer/Principal | |
| MORGAN STANLEY | Investment Managers | Corporate Officer/Principal |
Statistik
International
| Dänemark | 16 |
| Vereinigte Staaten | 13 |
| Niederlande | 7 |
| Frankreich | 5 |
| Vereinigtes Königreich | 4 |
Sektoral
| Health Technology | 36 |
| Finance | 7 |
| Consumer Services | 5 |
| Commercial Services | 4 |
| Process Industries | 2 |
Operativ
| Director/Board Member | 283 |
| Chairman | 86 |
| Corporate Officer/Principal | 71 |
| Independent Dir/Board Member | 59 |
| Chief Executive Officer | 54 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Amy Schulman | 45 |
| Bo Jesper Hansen | 34 |
| Georges Gemayel | 33 |
| Martijn Kleijwegt | 33 |
| Anders Hedegaard | 30 |
| Rémi Droller | 29 |
| Catherine Moukheibir | 29 |
| Sten Verland | 28 |
| Luc Dochez | 26 |
| Martin N. Bonde | 22 |
| Henrijette Richter | 21 |
| Klaus Breiner | 16 |
| Isaac E. Ciechanover | 16 |
| Donald Nicholson | 15 |
| Kim Stratton | 14 |
- Börse
- Insiders
- Anders Hinsby
- Unternehmensverbindungen
